Merck announces phase 3 study of its COVID-19 drug

Wednesday, 01. September 2021 13:06

Merck & Co. Inc. announced on Wednesday it has started the phase 3 clinical trial of its COVID-19 drug named molnupiravir with biotech company Ridgeback Biotherapeutics.

"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease. If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities," noted r. Nick Kartsonis, senior vice president Merck Research Laboratories.

The first results of the research can be expected to arrive during the second half of 2021.

Related Links: Merck & Co. Inc.
Breaking the News / ND